SPS
IMNM icon

Susquehanna Portfolio Strategies’s Immunome IMNM Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$966K Hold
44,164
– – 0.01% 643
2025
Q4 		$949K Hold
44,164
– – 0.01% 660
2025
Q3 		$517K Buy
+44,164
New +$439K 0.01% 830

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Susquehanna Portfolio Strategies's IMNM Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its Immunome (IMNM) position steady in Q1 2026 at 44,164 shares worth $966K. The position accounts for 0.01% of the portfolio, ranked #643.

Susquehanna Portfolio Strategies first reported a position in IMNM in Q3 2025 and has held it in 3 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Susquehanna Portfolio Strategies held 44,164 shares of Immunome worth $966K as of Q1 2026.
  • Susquehanna Portfolio Strategies left its Immunome share count unchanged in Q1 2026.
  • Immunome made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #643 holding.
  • Susquehanna Portfolio Strategies first reported a position in Immunome in Q3 2025 and has held it in 3 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.